Transgene SA

Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

01 апр 2025 11:45:00 Источник Nasdaq GlobeNewswire

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

27 мар 2025 12:45:00 Источник Nasdaq GlobeNewswire

Transgene to Participate in Upcoming Investor Meetings

11 мар 2025 12:45:00 Источник Nasdaq GlobeNewswire

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

06 фев 2025 11:45:00 Источник Nasdaq GlobeNewswire

Transgene to Participate in the Biomed Forum Investor Conference

21 янв 2025 11:45:00 Источник Nasdaq GlobeNewswire

Transgene Announces Financial Calendar for 2025

14 янв 2025 11:45:00 Источник Nasdaq GlobeNewswire

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

07 янв 2025 12:00:00 Источник Nasdaq GlobeNewswire

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

07 ноя 2024 11:45:00 Источник Nasdaq GlobeNewswire

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

07 ноя 2024 11:45:00 Источник Nasdaq GlobeNewswire

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

05 ноя 2024 01:30:00 Источник Nasdaq GlobeNewswire

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

14 окт 2024 01:30:00 Источник Nasdaq GlobeNewswire

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

07 окт 2024 02:00:00 Источник Nasdaq GlobeNewswire

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

24 сен 2024 11:45:00 Источник Nasdaq GlobeNewswire

Availability of Transgene’s Half-Year Financial Report as of June 30, 2024

24 сен 2024 11:45:00 Источник Nasdaq GlobeNewswire

2024 Half-Year Financial Report

24 сен 2024 11:45:00 Источник Nasdaq GlobeNewswire

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

14 сен 2024 03:05:00 Источник Nasdaq GlobeNewswire

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

10 сен 2024 01:30:00 Источник Nasdaq GlobeNewswire

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

09 сен 2024 01:00:00 Источник Nasdaq GlobeNewswire

Transgene to Participate in HTID Conference and Investor Access Forum in Paris

05 сен 2024 11:45:00 Источник Nasdaq GlobeNewswire

Transgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC

27 авг 2024 01:30:00 Источник Nasdaq GlobeNewswire